Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which clues predict survival in newborns with pulmonary hypertension?

NCT ID NCT07822750

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers at Assiut University Children Hospital are following 60 newborns diagnosed with pulmonary hypertension, a condition where high blood pressure in the lungs makes breathing difficult. The study collects clinical, laboratory, and heart ultrasound data to see which early signs predict whether babies survive to hospital discharge, how long they need breathing machines or oxygen, and whether they receive medications like sildenafil or inotropes. The goal is to help doctors recognize which infants face the highest risk and adjust care accordingly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers identify which early signs predict outcomes, doctors could better tailor monitoring and treatment for newborns with pulmonary hypertension.
What could go wrong
This is an observational study at a single hospital, so the findings may not apply to other settings. It cannot prove that any treatment causes better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Term and preterm neonates admitted to the Neonatal Intensive Care Unit of Assiut University Children Hospital with clinical and echocardiographic evidence of persistent pulmonary hypertension.

Ages

Up to 28 days

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Neonates (term and preterm) admitted to the NICU * Clinical and echocardiographic evidence of pulmonary hypertension * Written informed consent from parents or legal guardians Exclusion Criteria: * \- Major structural cyanotic congenital heart disease * Lethal congenital anomalies or chromosomal abnormalities incompatible with survival

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension, pulmonary are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infant, Newborn, Diseases perinatal disease persistent fetal circulation syndrome pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension, pulmonary Infant, newborn, diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.